General
Preferred name
CIMETIDINE
Synonyms
SKF-92334 ()
CIMETIDINE HYDROCHLORIDE ()
Cimal ()
Zita ()
Valmagen ()
Dyspamet ()
Kentamet ()
Peptimax 800 ()
Aciloc ()
Gastromet ()
Ultec ()
Tagamet ()
Tagadine ()
Tagamet HB ()
NSC-335308 ()
Ulcedin ()
Tagamet 100 ()
Stomedine ()
Ulcimet ()
Acid-eze ()
Peptimax 200 ()
Peptimax 400 ()
Brumetidina ()
Brumetadina ()
Cimetidinum ()
Galenamet ()
Tagamet HB 200 ()
Ulcomedina ()
Cimetidina ()
Acinil ()
Acitak 400 ()
Acitak 800 ()
Acitak 200 ()
Cimetidine hcl ()
Cimetidine-d3 ()
P&D ID
PD001634
CAS
51481-61-9
71989-90-7
2984-61-4
1185237-29-9
Tags
available
drug
biased GPCR ligand
Approved by
FDA
First approval
1977
Drug indication
Acid-reflux disorder
Gastroesophageal reflux disease
Drug Status
approved
investigational
Max Phase
4.0
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION Cimetidine is a histamine H2 receptor antagonist. (GtoPdb)
DESCRIPTION Cimetidine (SKF-92334) is an orally active and inverse histamine H2 receptor antagonist with a Ki of 0.6 ¦ÌM. Cimetidine is a gastric acid reducer, and can be used for duodenal and gastric ulcers research. Cimetidine has anti-cancer and anti-inflammatory activity[1][2][5].
PRICE 29
DESCRIPTION inhibitor of histidine receptor H2 (Informer Set)
DESCRIPTION H2 antagonist, I1 agonist (Tocriscreen Plus)
DESCRIPTION H2 Histamine receptor antagonist; anti-ulcer agent (LOPAC library)
DESCRIPTION H2 antagonist, I1 agonist (Tocriscreen Total)
DESCRIPTION Potent and selective group I mGlu antagonist (Tocris Bioactive Compound Library)
DESCRIPTION Cimetidine is a histamine-2 (H2) receptor antagonist. It is used to manage GERD, peptic ulcer disease, and indigestion. (Enamine Bioactive Compounds)
DESCRIPTION Cimetidine (SKF-92334) is a histamine congener, it competitively inhibits HISTAMINE binding to HISTAMINE H2 RECEPTORS. Cimetidine has a range of pharmacological actions. It inhibits GASTRIC ACID secretion, as well as PEPSIN and GASTRIN output. (TargetMol Bioactive Compound Library)
Cell lines
0
Organisms
1
Compound Sets
37
BiasDB
Cimetidine
Cayman Chemical Bioactives
18743
29050
ChEMBL Approved Drugs
CHEMBL30
CHEMBL1201051
ChEMBL Drugs
CHEMBL30
CHEMBL1201051
Concise Guide to Pharmacology 2017/18
1231
Concise Guide to Pharmacology 2019/20
1231
Concise Guide to Pharmacology 2021/22
1231
Concise Guide to Pharmacology 2023/24
1231
CZ-OPENSCREEN Bioactive Library
Drug Repurposing Hub
DrugBank
DB00501
DrugBank Approved Drugs
DB00501
DrugCentral
645
DrugCentral Approved Drugs
645
DrugMAP
DMH61ZB
DrugMAP Approved Drugs
DMH61ZB
DrugMatrix
Enamine Bioactive Compounds
EBC-04238
Enamine BioReference Compounds
Guide to Pharmacology
1231
Informer Set
26870
Ki Database
CIMETIDINE
LOPAC library
LSP-MoA library (Laboratory of Systems Pharmacology)
CHEMBL30
MedChem Express Bioactive Compound Library
HY-14289
NCATS Inxight Approved Drugs
80061L1WGD
NIH Clinical Collections (NCC)
NPC Screening Collection
Prestwick Chemical Library
ReFrame library
Selleckchem Bioactive Compound Library
Cimetidine(Tagamet)
TargetMol Bioactive Compound Library
T0797
The Spectrum Collection
Tocris Bioactive Compound Library
0902
Tocriscreen Plus
0902
Tocriscreen Total
ZINC Tool Compounds
ZINC000018115268
External IDs
100
Properties
(calculated by RDKit )
Molecular Weight
252.12
Hydrogen Bond Acceptors
4
Hydrogen Bond Donors
3
Rotatable Bonds
5
Ring Count
1
Aromatic Ring Count
1
cLogP
0.6
TPSA
88.89
Fraction CSP3
0.5
Chiral centers
0.0
Largest ring
5.0
QED
0.31
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Target
HRH2
HRH2, SLC29A4, SLC47A1, SLC47A2
Bacterial
Histamine Receptor
H2 receptor
Compound status
FDA
Target Type
7-TM Receptors
Selectivity
H2
Pathway
GPCR/G protein
Immunology/Inflammation
Neuroscience
Anti-infection
Neuronal Signaling
Primary Target
Histamine H2 Receptors
MOA
Antagonist
Histamine Receptor antagonist
Indication
duodenal ulcer disease, peptic ulcer disease (PUD), gastroesophageal reflux disease (GERD), aggressive systemic mastocytosis (ASM), Zollinger-Ellison syndrome, endocrine adenoma
Disease Area
gastroenterology, hematologic malignancy, endocrinology
Therapeutic Class
Antiulcer Agents
Source data